Household Transmission Investigation Study for COVID-19 in Tropical Regions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

245 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-23

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed coronavirus case in order to provide useful information on the proportion of symptomatic forms and the extent of the virus transmission in tropical regions such as French Guiana, Guadeloupe and New-Caledonia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Frequency and Distribution of Mixed Falciparum-vivax Infections in French Guiana

NCT02903758

Malaria

COMPLETED

Antimalarial Drug Resistance in Mali

NCT00127998

Malaria

COMPLETED NA

P. Falciparum Infection Dynamics and Transmission to Inform Elimination

NCT04053907

Malaria

UNKNOWN NA

The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers

NCT06651372

Arbovirus Infections

ACTIVE_NOT_RECRUITING

Evaluation of a New Malaria Control Strategy Amongst Gold Miners Working Illegally in French Guiana (Malakit)

NCT03695770

Malaria Public Health

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed coronavirus case in order to provide useful information on the proportion of symptomatic forms and the extent of the virus transmission in tropical regions such as French Guiana, Guadeloupe and New-Caledonia.

Subjects will be assessed (questionnaires and sampling) in their homes. Subjects will be asked to attend study visits at days 0, 7, 14, 21, 28, 60, 90, 180 and 360.

The primary objective of the study is to evaluate the rate of intra-household secondary transmission of the virus.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronavirus Infections Severe Acute Respiratory Syndrome SARS-CoV Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Primary case

Subject with laboratory-confirmed coronavirus SARS-CoV-2 infection by polymerase chain reaction (PCR)

Group Type EXPERIMENTAL

Human biological samples

Intervention Type PROCEDURE

* Blood sample
* Nasopharyngeal swab.

Family contact

Subject who lived in the household of the primary case while the primary case was symptomatic

Group Type EXPERIMENTAL

Human biological samples

Intervention Type PROCEDURE

* Blood sample
* Nasopharyngeal swab.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Human biological samples

* Blood sample
* Nasopharyngeal swab.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary case: laboratory-confirmed coronavirus SARS-CoV-2 infection by polymerase chain reaction (PCR),

or Family contact in French Guiana and Guadeloupe: person who lived in the same household as the primary case of COVID-19 when the primary case was symptomatic. A household is defined as a group of people (2 or more) living in the same accommodation (excluding residential institutions such as boarding schools, dormitories, hostels, prisons, other communities hosting grouped people),

or Close contact in New-Caledonia: any individual who was in contact with a primary case, in his/her family/living environment, work/school, friends/leisure or means of transport, when the primary case was symptomatic or presymptomatic,

* Affiliated or beneficiary of a social security system
* Informed consent prior to initiation of any study procedures from subject (or legally authorized representative)
* State of health compatible with a blood sample as defined in the protocol.

Exclusion Criteria

* Inability to consent
* Person under guardianship or curatorship
* Known pathology or a health problem contraindicated with the collect of blood sample.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes